MENLO PARK, Calif.,
Dec. 7, 2016 /PRNewswire/
-- BioPharmX Corporation (NYSE MKT: BPMX), a specialty
pharmaceutical company developing products for the dermatology
market, will share research at the Antibacterial Discovery and
Development Summit in Boston that
suggests topical delivery of minocycline may be effective for the
treatment of acne because, in topical form, minocycline may fight
P. acnes-induced local inflammation.
The study, which for the first time evaluates topical
minocycline efficacy in a murine model of acne, suggested that a
topical formulation effectively delivered minocycline into the skin
and improved efficacy against P. acnes. Results will be
showcased in a poster Thursday.
Presentation Details:
Title: "Therapeutic Effects of a Topical Minocycline in
an Inflammatory Skin Disorder Animal Model,"
Presenter: Usha Nagavarapu, Ph.D.
Location: The Revere Hotel, Boston
Time: 9:35 a.m. ET
The research is notable because it represents the first analysis
of minocycline's impact on inflammatory acne-like lesions in an
animal model. Previous studies have focused on P. acnes
reduction and acne lesion reduction rather than the P.
acnes-related inflammation that may cause or aggravate
acne.
"Minocycline is a proven anti-inflammatory drug and commonly
used to treat moderate-to-severe acne," said G. Scott Herron, a board-certified dermatologist
and fellow of the American Academy of Dermatology. "Minocycline's
anti-inflammatory benefits may be even more effective when
delivered in a low dose topical formulation as the delivery is both
targeted and localized."
BPX-01, BioPharmX's unique topical minocycline gel formulation
is the first and only stable hydrophilic (non-oil-based) topical
gel with fully solubilized minocycline that can penetrate the skin
to deliver the antibiotic to the layer of skin where the acne
develops in the pilosebaceous unit.The company's studies are
designed to confirm whether BPX-01 will effectively treat acne with
lower, and potentially safer, dosages of the antibiotic.
BioPharmX recently initiated a Phase 2b dose-finding study,
called the OPAL Trial (tOPicAL minocycline gel), that is a 12-week,
multi-center, randomized, double-blind, three-arm, vehicle
controlled study and will enroll 225 subjects, aged 9 to 40, with
moderate-to-severe inflammatory, non-nodular acne vulgaris.
The American Academy of Dermatology calls acne the "most common
skin condition in the United States," affecting 40 million to 50
million Americans. The U.S. market for acne medications is
estimated at $10 billion.
About BioPharmX® Corporation
BioPharmX Corporation
(NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical
company that seeks to provide products through proprietary platform
technologies for prescription, over-the-counter and supplement
applications in dermatology. To learn more about BioPharmX, visit
www.BioPharmX.com.
Forward-Looking Statement
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the "safe harbor" created by those
sections. This press release contains forward-looking statements
about the company's expectations, plans, intentions and strategies,
including, but not limited to, statements regarding, the
effectiveness of topical minocycline on the treatment of acne and
inflammation, and the results delivered by the Company's Phase 2b
dose-finding study. These forward-looking statements may be
identified by words such as "plan", "expect," "anticipate,"
"believe," or similar expressions that are intended to identify
such forward-looking statements. These forward-looking statements
involve risks and uncertainties, as well as assumptions, which, if
they do not fully materialize or prove incorrect, could cause our
results to differ materially from those expressed or implied by
such forward-looking statements. The risks and uncertainties
include those described in the company's filings with the
Securities and Exchange Commission. Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements. The forward-looking statements
included in this news release are made only as of the date hereof
and the company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required
under applicable securities laws.
BioPharmX is a registered trademark of BioPharmX, Inc.
Logo - http://photos.prnewswire.com/prnh/20150711/235327LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biopharmx-to-present-evidence-that-bpx-01-topical-minocycline-gel-may-reduce-acne-associated-inflammation-300374123.html
SOURCE BioPharmX Corporation